Prevention & Treatment

December 17, 2024

COVID-19 Vaccine Prevents Deaths of Cancer and CLL Patients

The COVID-19 mortality rate was lower in recently vaccinated cancer patients and the same was true for B-cell cancers, including those with CLL.

December 17, 2024

Nirmatrelvir-Ritonavir (Paxlovid) for the Immunocompromised with COVID-19

Nirmatrelvir-ritonavir (Paxlovid) reduced the risk of death among immunocompromised patients who were hospitalized with COVID-19.

May 21, 2024

CLL Society’s Official Statement on Mask Wearing and Other Protective Measures for Those Living with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) in Healthcare Settings

CLL Society has created our Statement on Mask Wearing and Other Protective Measures for Those Living with CLL to protect against respiratory infections spread.

December 15, 2023

NIH Home Test to Treat Program

Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.

August 25, 2023

New COVID-19 Vaccine Clinical Trial Specifically for Those with CLL and Other Blood Cancers

Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.

July 3, 2023

Study Understanding Pre-Exposure Prophylaxis of Novel Antibodies (SUPERNOVA)

Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.

February 6, 2023

CLL Society’s Official Statement Regarding Workplace Accommodations for People with CLL / SLL While There is Risk of COVID-19 Exposure (Update 2/6/2023)

As the risk of COVID-19 exposure stretches on, we have updated our official statement concerning working conditions for people with CLL / SLL (Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma) that you can download for your own reference and to share with the appropriate people in your life including HR and co-workers.

September 13, 2022

Dr. Shmuel Shoham on Convalescent Plasma for COVID-19 in Immunocompromised Patients

In this interview, Dr. Brian Koffman spoke with Dr. Shmuel Shoham, a Professor of Clinical Medicine at Johns Hopkins University. Dr. Shoham specializes in the infectious disease care of immunocompromised patients, including those with leukemias and lymphomas. They discussed the use of convalescent plasma to treat COVID-19.

June 20, 2022

Dr. Diamond on Building a Better COVID-19 Vaccine for the Immunocompromised

Don Diamond. Ph.D., has been working for decades at City of Hope, Duarte, CA, constructing a new vaccine platform that will benefit the immunocompromised. It’s already been successfully used in post allogeneic hematopoietic stem cell (bone marrow) transplants to prevent a different viral infection, CMV.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Prevention & Treatment

COVID-19 Vaccine Prevents Deaths of Cancer and CLL Patients

Nirmatrelvir-Ritonavir (Paxlovid) for the Immunocompromised with COVID-19

CLL Society’s Official Statement on Mask Wearing and Other Protective Measures for Those Living with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) in Healthcare Settings

NIH Home Test to Treat Program

New COVID-19 Vaccine Clinical Trial Specifically for Those with CLL and Other Blood Cancers

Study Understanding Pre-Exposure Prophylaxis of Novel Antibodies (SUPERNOVA)

CLL Society’s Official Statement Regarding Workplace Accommodations for People with CLL / SLL While There is Risk of COVID-19 Exposure (Update 2/6/2023)

Dr. Shmuel Shoham on Convalescent Plasma for COVID-19 in Immunocompromised Patients

Dr. Diamond on Building a Better COVID-19 Vaccine for the Immunocompromised

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT